Prosecution Insights
Last updated: August 15, 2026
Application No. 18/511,347

IN VITRO MODEL DEVICE FOR PLACENTAL BARRIER

Final Rejection §112
Filed
Nov 16, 2023
Priority
Nov 16, 2022 — provisional 63/384,011
Examiner
FRISBY, KESHA
Art Unit
3715
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Cfd Research Corporation
OA Round
2 (Final)
53%
Grant Probability
Moderate
3-4
OA Rounds
11m
Est. Remaining
76%
With Interview

Examiner Intelligence

Grants 53% of resolved cases
53%
Career Allowance Rate
403 granted / 765 resolved
-17.3% vs TC avg
Strong +24% interview lift
Without
With
+23.7%
Interview Lift
resolved cases with interview
Typical timeline
3y 8m
Avg Prosecution
29 currently pending
Career history
798
Total Applications
across all art units

Statute-Specific Performance

§101
23.8%
-16.2% vs TC avg
§103
36.1%
-3.9% vs TC avg
§102
22.6%
-17.4% vs TC avg
§112
14.7%
-25.3% vs TC avg
Black line = Tech Center average estimate • Based on career data from 765 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 21-30 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Further, claims 21-30 are rejected as Independent claims 21 & 23 are providing and determining information. There is no end result. In other words, what happens after this is information is provided or determined. Some claims are rejected due to their dependencies. Allowable Subject Matter Claims 1 & 11-20 are allowed. The following is an examiner’s statement of reasons for allowance: None of the cited patents and/or publications used together or separately teach which is configured as a microfluidic in vitro model of a placenta. Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled “Comments on Statement of Reasons for Allowance.” Response to Arguments Applicant's arguments filed 5/26/2026 have been fully considered but they are not persuasive. The manner in which the claims have been amended does not over the current 35 USC 112 rejection because the Applicant just amended the claims to add another determining step. All, that is being done is information is determined but again there is no end result or product/production done. Therefore, the above current 35 USC 112 rejection is still upheld by the Examiner. All other 35 USC 112 rejections have been withdrawn. Conclusion THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to KESHA FRISBY whose telephone number is (571)272-8774. The examiner can normally be reached Monday-Friday 730AM-4PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Xuan Thai can be reached at 571-272-7147. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /KESHA FRISBY/Primary Examiner, Art Unit 3715
Read full office action

Prosecution Timeline

Nov 16, 2023
Application Filed
Dec 27, 2025
Non-Final Rejection (signed) — §112
Mar 04, 2026
Non-Final Rejection mailed — §112
May 26, 2026
Response Filed
Jun 17, 2026
Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12705996
RECIPE CONVERSION SYSTEM
5y 11m to grant Granted Aug 11, 2026
Patent 12706003
FLEXIBLE SPINE MODEL AND CORRECTION DEMONSTRATION AND TEST SYSTEM IMPLEMENTED BASED ON SAME
2y 9m to grant Granted Aug 11, 2026
Patent 12698949
PERSONALIZED COMBAT SIMULATION EQUIPMENT
2y 6m to grant Granted Aug 04, 2026
Patent 12646424
SURGICAL TRAINING MODEL INCLUDING A SIMULATED HUMAN PROSTATE AND ASSOCIATED METHODS
2y 10m to grant Granted Jun 02, 2026
Patent 12640054
COMPUTATIONAL IN SILICO MODEL FOR PLACENTAL BARRIER
2y 6m to grant Granted May 26, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
53%
Grant Probability
76%
With Interview (+23.7%)
3y 8m (~11m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 765 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month